Amgen (AMGN) Intangibles (2009 - 2026)
Amgen (AMGN) posted Intangibles of $20.5 billion for Q2 2026, down 4.17% on a QoQ basis from $21.4 billion in Q1 2026, and down 16.77% year-over-year from $24.6 billion in Q2 2025.
Analysis
Amgen (AMGN) Intangibles (2009 - 2026) Analysis & Trends
Amgen has reported Intangibles for 18 years, with the latest figure at $20.5 billion in Q2 2026.
- On a quarterly basis, Intangibles fell 16.77% year-over-year to $20.5 billion in Q2 2026; TTM through Jun 2026 was $20.5 billion, a 16.77% decrease from a year earlier, with the FY2025 full-year figure at $22.3 billion, down 19.58% from the prior year.
- Intangibles was $20.5 billion for Q2 2026 at Amgen, down from $21.4 billion in the prior quarter.
- The five-year high for Intangibles was $32.6 billion in Q4 2023, with the low at $13.2 billion in Q3 2023.
- Average Intangibles over 5 years is $21.6 billion, with a median of $21.8 billion recorded in 2025.
- The sharpest annual moves came in 2024 and 2025: Intangibles soared 119.92% in 2024, then declined 19.99% in 2025.
- Over 5 years, Intangibles stood at $16.1 billion in 2022, then soared by 102.99% to $32.6 billion in 2023, then fell by 15.14% to $27.7 billion in 2024, then declined by 19.58% to $22.3 billion in 2025, then declined by 8.03% to $20.5 billion in 2026.
- The last three Intangibles figures came in at $20.5 billion (Q2 2026), $21.4 billion (Q1 2026), and $22.3 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 20.49 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 14.03 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 412.80 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 1.31 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 266.00 Mn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 13.52 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | 93.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.49 Bn |
| Mar 31, 2026 | 21.38 Bn |
| Dec 31, 2025 | 22.28 Bn |
| Sep 30, 2025 | 23.14 Bn |
| Jun 30, 2025 | 24.61 Bn |
| Mar 31, 2025 | 25.72 Bn |
| Dec 31, 2024 | 27.70 Bn |
| Sep 30, 2024 | 28.92 Bn |
| Jun 30, 2024 | 30.17 Bn |
| Mar 31, 2024 | 31.37 Bn |
| Dec 31, 2023 | 32.64 Bn |
| Sep 30, 2023 | 13.15 Bn |
| Jun 30, 2023 | 14.63 Bn |
| Mar 31, 2023 | 15.39 Bn |
| Dec 31, 2022 | 16.08 Bn |
| Sep 30, 2022 | 13.27 Bn |
| Jun 30, 2022 | 13.93 Bn |
| Mar 31, 2022 | 14.57 Bn |
| Dec 31, 2021 | 15.18 Bn |
| Sep 30, 2021 | 14.66 Bn |